Condition: Non-obstructive Hypertrophic Cardiomyopathy · Sponsor: Imbria Pharmaceuticals, Inc.
The purpose of this study is to assess the safety, tolerability, and potential efficacy of IMB-1018972 in patients with non-obstructive HCM.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Imbria Investigational Site | La Jolla, California, United States | — |
| Imbria Investigational Site | Los Angeles, California, United States | — |
| Imbria Investigational Site | San Francisco, California, United States | — |
| Imbria Investigational Site | Chicago, Illinois, United States | — |
| Imbria Investigational Site | Boston, Massachusetts, United States | — |
| Imbria Investigational Site | Burlington, Massachusetts, United States | — |
| Imbria Investigational Site | St Louis, Missouri, United States | — |
| Imbria Investigational Site | Morristown, New Jersey, United States | — |
| Imbria Investigational Site | New York, New York, United States | — |
| Imbria Investigational Site | Charlotte, North Carolina, United States | — |
| Imbria Investigational Site | Portland, Oregon, United States | — |
| Imbria Investigational Site | Houston, Texas, United States | — |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04826185